fus1 Antibody

What is FUS1 and why are antibodies against it important in cancer research?

FUS1 (also known as TUSC2) is a novel candidate tumor suppressor gene identified in human chromosome 3p21.3. Its expression shows significant reduction or loss in lung cancer and other types of cancers . FUS1 antibodies are critical research tools that enable detection of both recombinant exogenous FUS1 and endogenous FUS1 from tissues and cells through western blot and immunohistochemistry . This allows researchers to investigate the biological function of FUS1, which is essential for understanding its tumor suppression mechanisms.

When selecting antibodies, researchers should note that both polyclonal and monoclonal options are available. Polyclonal antibodies against human FUS1 have been successfully produced by immunizing rabbits with purified recombinant FUS1 proteins , offering broad epitope recognition for detection purposes.

How can I distinguish between FUS1 (tumor suppressor) and FUS (RNA-binding protein) in my research?

Despite similar names, these are distinct proteins with different functions:

• FUS1 (TUSC2): A tumor suppressor gene product implicated primarily in lung cancer

• FUS (Fused in Sarcoma): An RNA-binding protein associated with neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia

For accurate research:

• Verify antibody specificity using appropriate controls

• Check molecular weight (FUS1 is approximately 21 kDa; FUS is ~70 kDa)

• Confirm subcellular localization patterns differ (FUS primarily nuclear in healthy cells)

• Use knockout or knockdown validation approaches specific to your protein of interest

What applications are FUS1 antibodies suitable for in laboratory research?

FUS1 antibodies have been successfully employed in multiple applications:

Each application requires specific validation approaches, including the use of positive controls (such as MRC-5 cells) and negative controls .

How does FUS1 protein myristoylation affect antibody recognition and experimental design?

Myristoylation of FUS1 at the N-terminus is critical for its tumor suppressor function. Research indicates that myristoylation increases the half-life of the FUS1 protein, and absence of myristoylation has been observed in NSCLC primary tumors . This post-translational modification has significant implications for antibody-based research:

• Epitope accessibility may differ between myristoylated and non-myristoylated forms

• Subcellular localization is affected by myristoylation status, impacting immunostaining patterns

• When comparing wild-type versus myristoylation-deficient FUS1 (e.g., G2A mutation), antibody selection is crucial

• Functional studies should include controls that discriminate between both forms

Co-expression of c-ABL with a myristoylation-deficient mutant of FUS1 resulted in minimal decreases in phosphotyrosine c-Abl compared to wild-type FUS1, highlighting the functional importance of this modification .

What challenges exist in detecting mutant forms of FUS1 in cancer samples?

A C-terminal deletion mutant of FUS1 (FUS1 1-80) has been isolated from lung cancer cell lines, encoding only the first 80 amino acids of the 110-amino-acid wild-type protein . This creates several detection challenges:

• Antibodies targeting the C-terminal region cannot recognize the truncated protein

• The mutant protein may exhibit altered stability and expression levels

• Different subcellular localization patterns may emerge due to missing functional domains

• The mutant lacks the tumor-suppressive properties of wild-type FUS1

To address these challenges:

• Use antibodies targeting the N-terminal region preserved in both forms

• Employ multiple detection methods (protein and mRNA analysis)

• Consider size differences in western blot analysis

• Sequence samples to confirm specific mutations when possible

How does the FUS1-c-Abl interaction mechanism influence experimental approaches?

Research demonstrates that FUS1 negatively regulates c-Abl tyrosine kinase activity. When designing experiments to study this interaction:

• Co-expression of wild-type FUS1 with c-ABL significantly inhibits phosphorylation of tyrosine 412 on c-Abl, a critical indicator of c-Abl activation

• The truncated FUS1(1-80) mutant has minimal inhibitory effects on c-Abl phosphorylation

• Immunoprecipitation with FUS1 antibodies co-precipitates c-Abl, suggesting direct association

• Expression of wild-type FUS1 reduces both phosphorylation of tyrosine 245 and total c-Abl protein levels

A stearate-FUS1 peptide derived from sequences deleted in the mutant FUS1 strongly inhibits Abl kinase activity, providing a potential research tool . These findings suggest screening for c-Abl activation status alongside FUS1 expression in cancer studies.

What are optimal protocols for FUS1 antibody production and purification?

Based on established methodologies:

• Expression system selection:

  • Prokaryotic expression in E. coli (e.g., M15 strain) using vectors like pQE-30 has been successful for producing recombinant FUS1

  • Optimal induction conditions: 0.5 mM IPTG for 5 hours at 37°C

• Protein purification approach:

  • Inclusion bodies containing recombinant FUS1 can be solubilized in 2M urea

  • Histidine-tagged purification using affinity chromatography under denaturing conditions works effectively

  • Verification by electrospray ionization-mass spectrometry (ESI-MS) and HPLC chromatography ensures purity

• Antibody production:

  • Immunization of rabbits with purified recombinant FUS1 generates effective polyclonal antibodies

  • These antibodies can detect both recombinant exogenous and endogenous FUS1 in tissues and cells

How should researchers validate FUS1 antibody specificity?

A comprehensive validation approach includes:

• Western blot analysis comparing:

  • Cell lines with known FUS1 expression versus knockout models

  • Wild-type versus FUS1 mutant (FUS1 1-80) expressing cells

  • Molecular weight verification (approximately 21 kDa for full-length FUS1)

• Immunoprecipitation validation:

  • Assess antibody performance in immunopurifying FUS1 from cell extracts

  • Evaluate both the immunoprecipitated fraction and immunodepleted extracts

  • Confirm identity through mass spectrometry analysis

• Cross-technique comparison:

  • Correlate results between western blot, immunohistochemistry, and flow cytometry

  • Use standardized experimental protocols across techniques

  • Employ knockout cell lines and isogenic parental controls as definitive validation

What experimental controls are essential when studying FUS1 using antibodies?

Essential controls include:

• Expression controls:

  • Positive controls: Cell lines with confirmed FUS1 expression (e.g., MRC-5 cells)

  • Negative controls: FUS1 knockout cell lines or lines with naturally low expression

• Antibody specificity controls:

  • Secondary antibody-only controls to assess background

  • Isotype controls matched to primary antibody class and species

  • Peptide competition assays where pre-incubation with purified FUS1 should block signal

• Functional controls:

  • Wild-type FUS1 versus myristoylation-deficient FUS1 (G2A mutant)

  • Full-length FUS1 versus truncated FUS1(1-80) mutant

  • Inducible expression systems to monitor dose-dependent effects

How can researchers resolve common issues with FUS1 antibody applications?

When troubleshooting, consider that FUS1 expression levels vary significantly between normal and cancer tissues , and post-translational modifications may affect antibody recognition.

How should researchers interpret FUS1 and c-Abl co-detection data?

When analyzing FUS1 and c-Abl relationships:

• Expression correlation analysis:

  • Decreased phosphorylation of tyrosine 245 and 412 on c-Abl indicates FUS1-mediated inhibition

  • Total c-Abl protein levels may decrease with FUS1 expression, suggesting FUS1 promotes c-Abl degradation

• Interaction assessment:

  • Co-immunoprecipitation can confirm physical association between FUS1 and c-Abl

  • Proximity ligation assays can visualize interactions in situ

• Functional readouts:

  • Total cellular phosphotyrosine patterns decrease upon FUS1 induction

  • Cell death (measured by TUNEL staining) increases with wild-type FUS1 expression but not with myristoylation-deficient mutants

This data interpretation is particularly relevant for lung cancer research, as c-Abl appears to be a possible target in NSCLC patients with reduced FUS1 expression .

What emerging applications might FUS1 antibodies have in cancer biomarker development?

Future research applications include:

• Diagnostic and prognostic marker development:

  • Standardized immunohistochemistry protocols for clinical samples

  • Quantitative assays correlating FUS1 expression with patient outcomes

  • Development of antibody panels combining FUS1 with other cancer markers

• Therapeutic monitoring tools:

  • Antibodies detecting re-expression of FUS1 after treatment

  • Monitoring changes in downstream pathways (particularly c-Abl activity)

  • Liquid biopsy applications for circulating tumor cells

• Targeted therapy approaches:

  • The stearate-FUS1 peptide shows potential for c-Abl inhibition

  • Antibody-conjugated therapeutics targeting cells with aberrant FUS1 expression

  • Combination therapies targeting both FUS1 and c-Abl pathways

How might research on FUS1 antibodies advance our understanding of tumor suppressor mechanisms?

Advanced applications could include:

• Protein interaction studies:

  • ChIP-seq or CLIP-seq to identify DNA/RNA binding partners

  • Proximity ligation assays to study FUS1 protein interactions in situ

  • FRET-based assays to monitor FUS1-c-Abl interactions in live cells

• Post-translational modification mapping:

  • Development of modification-specific antibodies (phospho-, myristoylated-FUS1)

  • Correlation between modifications and tumor suppressor activity

  • Tracking changes in modification patterns during cancer progression

• Therapeutic development:

  • The inhibitory Fus1 sequence identified (derived from the region deleted in mutant FUS1) could be developed into peptide therapeutics

  • Imatinib mesylate and other c-Abl inhibitors might be particularly effective in tumors with reduced FUS1 expression

  • Combination approaches targeting both FUS1 re-expression and c-Abl inhibition

These approaches could reveal new mechanisms of tumor suppression beyond the established FUS1-c-Abl interaction, providing insights into cancer biology and potential therapeutic targets.